244
Abstract Views
78
PDF Download
Virology

Epitope-Driven Vaccine Development for Zika Virus: A Bioinformatics Approach

Riska Ayu Sutriyansyah Study Program of Biology, Faculty of Mathematics and Natural Sciences, Surabaya State University, Surabaya, Indonesia, Indonesia Correspondence ansori.anm@gmail.com
,
Muhamad Hilmi Ihsanul Iman Study Program of Biology, Faculty of Mathematics and Natural Sciences, Surabaya State University, Surabaya, Indonesia, Indonesia Correspondence ansori.anm@gmail.com
,
Cahya Ajeng Valenta Tresna Sulung Study Program of Biology, Faculty of Mathematics and Natural Sciences, Surabaya State University, Surabaya, Indonesia, Indonesia Correspondence ansori.anm@gmail.com
,
Nelly Indira Kusuma Wardani Study Program of Biology, Faculty of Mathematics and Natural Sciences, Surabaya State University, Surabaya, Indonesia, Indonesia Correspondence ansori.anm@gmail.com
,
Arif Nur Muhammad Ansori Universitas Airlangga, Indonesia Correspondence ansori.anm@gmail.com
ORCID : https://orcid.org/0000-0002-1279-3904
Pages 96-105
Browse this journal

Abstract

Zika virus (ZIKV) has become a global concern in 2015-2016, which can infect adults and developing fetuses. ZIKV is a member of the Flaviviridae family, which can spread through Aedes mosquitoes, sexual intercourse, from mother to fetus, and blood transfusions. The genetic material is single-stranded RNA with positive polarity. Conventional vaccine development requires a long time and significant resources, so the bioinformatics approach is an efficient alternative for identifying B cell epitopes as vaccine candidates. This research uses bioinformatics or In silico methods to identify B cell epitopes with the immune epitope database (IEDB) web server. This research showed that the peptide sequence of "EWFHDIPLPWHAGADTGTPHWNNKEA" (peptide 6E) in the envelope protein E of ZIKV is a potential vaccine candidate. This peptide is predicted to have high antigenicity, non-allergenicity and non-toxicity. This study concluded that peptide 6E is a promising vaccine candidate. Further studies are needed in vitro and in vivo to reconfirm that it can be used as a potential ZIKV vaccine candidate and can be applied in the future.

Keywords :

There is no Figure or data content available for this article

References

  • Masmejan S, Musso D, Vouga M, et al. Zika virus. Pathogens. 2020;9(11):898.
  • Pattnaik A, Sahoo BR, Pattnaik AK. Current status of Zika virus vaccines: successes and challenges. Vaccines (Basel). 2020;8(2):266.
  • Garg H, Mehmetoglu-Gurbuz T, Joshi A. Virus like particles (VLP) as multivalent vaccine candidate against chikungunya, Japanese encephalitis, yellow fever and zika virus. Sci Rep. 2020;10(1):4017. doi: 10.1038/s41598-020-61103-1.
  • Prasasty VD, Grazzolie K, Rosmalena R, Yazid F, Ivan FX, Sinaga E. Peptide-based subunit vaccine design of T-and B-cells multi-epitopes against Zika virus using immunoinformatics approaches. Microorganisms. 2019;7(8):226. https://doi.org/10.3390/microorganisms7080226.
  • Buitrago-Pabón AL, Ruiz-Sáenz S, Jiménez-Alberto A, Aparicio-Ozores G, Castelán-Vega JA, Ribas-Aparicio RM. An Update on Zika Virus Vaccine Development and New Research Approaches. Microbiol Res (Pavia). 2024;15(2):667-692.
  • Saha R, & PB V. In silico approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2). BioRxiv. 2020;03.
  • Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning. Front Immunol. 2020;11:1581.
  • Rauch S, Jasny E, Schmidt KE, Petsch B. New vaccine technologies to combat outbreak situations. Front Immunol. 2018;9:1963.
  • Ansori ANM, Kharisma VD, Muttaqin SS, Antonius Y, Parikesit AA. Genetic variant of SARS-CoV-2 isolates in Indonesia: Spike glycoprotein gene. J Pure Appl Microbiol. 2020;14(1):971-978. https://doi.org/10.22207/JP AM.14.SPL1.35.
  • Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296-W303. https://doi.org/10.1093/nar/gky427.
  • Kharisma VD, Agatha A, Ansori ANM, et al. Herbal combination from Moringa oleifera Lam. and Curcuma longa L. as SARS-CoV-2 antiviral via dual inhibitor pathway: A viroinformatics approach. J Pharm Pharmacogn Res. 2021;10(1):138-146.
  • Luqman A, KVD, RRA, GF. In silico and in vitro study of trace amines (TA) and dopamine (DOP) interaction with human alpha 1-adrenergic receptor and the bacterial adrenergic receptor QseC. Cell Physiol. Biochem,. 2020;54(5):888-898. https://doi.org/10.33594/000000276.
  • Satyanarayana SD V, Krishna MSR, Kumar PP, Jeereddy S. In silico structural homology modeling of nif A protein of rhizobial strains in selective legume plants. Journal of Genetic Engineering and Biotechnology. 2018;16(2):731-737. https://doi.org/10.1016/j.jgeb.20 18.06.006.
  • Oli AN, Obialor WO, Ifeanyichukwu MO, et al. Immunoinformatics and vaccine development: an overview. Immunotargets Ther. 2020:913-30. https://doi.org/10.2147/ITT.S241064.
  • Sumadi FAN, Ariadne AZS, Jamil AS, Muchlisin MA, Rachmawati H. In Silico Design Of B-Cell Epitope Based Peptide Vaccine for Zika Virus. Journal of Pharmacopolium. 2022;5(1).
  • Ebrahimi S, Mohabatkar H. Prediction of T-cell epitopes for designing a reverse vaccine against streptococcal bacteria. Mol Biol Res Commun. 2018;7(1):35. https://doi.org/10.22099/mbrc.2018.28775.1308.
  • Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2—a server for In silico prediction of allergens. J Mol Model. 2014;20:1-6. https//doi.org/10.1007/s00894-014-2278-5.
  • Gupta S, Kapoor P, Chaudhary K, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957. https://doi.org/10.1371/journal.pone.0073957.
  • Barman A, DB, CS. Prediction of potential epitopes for peptide vaccine formulation against Teschovirus A using immunoinformatics. Int JPept Res Ther. 2020;26(2):1137-1146. https://doi.org/10.1007/s10989-019-09916-1.
  • Abraham Peele K, Srihansa T, Krupanidhi S, Ayyagari VS, Venkateswarulu TC. Design of multi-epitope vaccine candidate against SARS-CoV-2: A in-silico study. J Biomol Struct Dyn. 2021;39(10):3793-3801. https://doi.org/10.1080/07391102.202 0.1770127.
  • Adianingsih OR, Kharisma VD. Study of B cell epitope conserved region of the Zika virus envelope glycoprotein to develop multi-strain vaccine. J Appl Pharm Sci. 2019;9(1):98-103.
  • Kharisma VD, Widodo N, Muhammad Ansori AN, Nugraha AP. A vaccine candidate of Zika virus (ZIKV) from polyvalent conserved b-cell epitope on viral glycoprotein: In silico approach. Biochem Cell Arch. 2020;20. https://doi.org/10.35124/bca.2020.20.S1.2785.
  • Raju S, Sahoo D, Bhari VK. In-silico Design of Multi-epitope Vaccine against Nipah Virus using Immunoinformatics Approach. J Pure Appl Microbiol. 2021;15(1). https://doi.org/1 0.22207/JPAM.15.1.16.
  • Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and methods for T?and B?cell epitope prediction. J Immunol Res. 2017;2017(1):2680160.
  • Tahir RA, Wu H, Rizwan MA, Jafar TH, Saleem S, Sehgal SA. Immunoinformatics and molecular docking studies reveal potential epitope-based peptide vaccine against DENV-NS3 protein. J Theor Biol. 2018;459:162-170. https://doi.org/10.1016/j.jtbi.2018.10.005.
  • Fahnert B, Lilie H, Neubauer P. Inclusion bodies: formation and utilisation. Physiological Stress Responses in Bioprocesses: -/-. Published online 2004:93-142.
  • Firmansyah MA, Susilo A, Haryanti SD, Herowati R. Desain Vaksin Berbasis Epitop dengan Pendekatan Bioinformatika untuk Menekan Glikoprotein Spike SARS-CoV-2. Jurnal Farmasi Indonesia. 2021;18(2):82-96.
  • Wickelgren I. Policing the immune system. Journal Of Science. 2004;306. https://doi.org/10.1126/science.306.5696.596.
  • Mulkey SB, Peyton C, Ansusinha E, et al. Preschool neurodevelopment in Zika virus-exposed children without congenital Zika syndrome. Pediatr Res. 2023;94(1):178-184.
  • Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity. 2010;33(4):492-503.
  • Gupta Y, Baranwal M, Chudasama B. Immunoinformatics-Based Identification of the Conserved Immunogenic Peptides Targeting of Zika Virus Precursor Membrane Protein. Viral Immunol. 2023;36(8):503-519.
  • Zhang X, Zhao B, Ding M, et al. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection. Theranostics. 2020;10(13):5704.
There is no Supplemental content for this article.

How to Cite This

Riska Ayu Sutriyansyah, Muhamad Hilmi Ihsanul Iman, Cahya Ajeng Valenta Tresna Sulung, Nelly Indira Kusuma Wardani, & Ansori, A. N. M. (2024). Epitope-Driven Vaccine Development for Zika Virus: A Bioinformatics Approach . Jurnal Teknologi Laboratorium, 13(2), 96–105. https://doi.org/10.29238/teknolabjournal.v13i2.518

Article Metrics

Download Statistics

Downloads

Download data is not yet available.

Other Statistics

Verify authenticity via CrossMark

Copyright and Permissions

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

Publishing your paper with Jurnal Teknologi Laboratorium (JTL) means that the author or authors retain the copyright in the paper. JTL granted an exclusive reuse license by the author(s), but the author(s) are able to put the paper onto a website, distribute it to colleagues, give it to students, use it in your thesis etc, even commercially. The author(s) can reuse the figures and tables and other information contained in their paper published by JTL in future papers or work without having to ask anyone for permission, provided that the figures, tables or other information that is included in the new paper or work properly references the published paper as the source of the figures, tables or other information, and the new paper or work is not direct at private monetary gain or commercial advantage.

JTL journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge. This journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets others remix, transform, and build upon the material for any purpose, even commercially.

JTL journal Open Access articles are distributed under this Creative Commons Attribution-ShareAlike 4.0 International License (CC BY-SA). Articles can be read and shared for All purposes under the following conditions:

  • BY: You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • SA:  If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

Data Availability

All data generated during this study are included in this published article [and its supplementary information files].